Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation

Although ibrutinib-related atrial fibrillation (IRAF) occurs in up to 11% of patients in clinical trials, these studies have rarely fully characterized bleeding events or risk factors for bleeding when ibrutinib is combined with anticoagulation. Furthermore, guidelines do not provide direction regarding the preferred anti-arrhythmic agent for IRAF.

Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Ahmad Halwani, MD Alaina Vrontikis Deborah M. Stephens, DO Jeffrey A. Gilreath, PharmD Jessica Carey John W. Sweetenham, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Source Type: news